Cerus Corporation Announces Record Results for Third Quarter 2025
Nov 6, 2025, 16:05 GMT-52 min read
 CERS-2.76%
Cerus Corporation has reported its financial results for the third quarter ended September 30, 2025, showcasing significant growth and operational achievements. The company, dedicated to safeguarding the world's blood supply, has seen a notable increase in revenue and has raised its full-year product revenue guidance.
Financial Highlights
For the third quarter of 2025, Cerus Corporation reported a total revenue of $60.2 million, marking a 19% increase from the $50.7 million reported in the same period of 2024. Product revenue reached a record $52.7 million, up 15% year-over-year, driven by strong global commercial execution and growing awareness of the INTERCEPT Blood System. Government contract revenue also saw a significant rise, increasing by 63% to $7.5 million.
The company's GAAP net loss narrowed to $0.02 million, nearly breakeven, compared to a net loss of $2.9 million in the prior year period. Non-GAAP adjusted EBITDA for the third quarter was $5.0 million, up from $4.4 million in the same period of 2024.
Business and Operational Highlights
Hospital demand for INTERCEPT Fibrinogen Complex (IFC) in the U.S. continues to grow, with third-quarter volumes up approximately 110% compared to the prior year period. U.S. IFC sales totaled $3.9 million, up from $2.3 million during the prior year period. Additionally, Cerus completed enrollment in the U.S. RedeS trial, a pivotal Phase 3 clinical trial evaluating the safety and efficacy of red blood cells prepared with the INTERCEPT Blood System for Red Blood Cells (RBCs).
Strategic Initiatives and Corporate Developments
Cerus has raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million, reflecting growth of 12% to 13% from 2024. This includes full-year 2025 IFC revenue guidance between $16 million to $17 million. The company also reported cash, cash equivalents, and short-term investments of $78.5 million as of September 30, 2025.
Management's Perspective
William “Obi” Greenman, Cerus’ president and chief executive officer, commented on the results, stating, “We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System.”
Future Outlook
The company expects full-year 2025 product revenue to be in the range of $202 million to $204 million, with IFC revenue guidance between $16 million to $17 million. Cerus is also well positioned to achieve its goal of positive full-year 2025 non-GAAP adjusted EBITDA.
Original SEC Filing: CERUS CORP [ CERS ] - 8-K - Nov. 06, 2025
Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC. |
